Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2026, Vol. 22 ›› Issue (05): 398 -409. doi: 10.3877/cma.j.issn.1673-5250.2026.05.004

Original Article

Analysis of newborns screening results for inborn errors of metabolism in Hainan Province

Xialin Fan1, Cidan Huang2, Qiaomiao Zhou2, Xia Cao1,3,†()   

  1. 1Department of Healthcare, Hainan Women and Children′s Medical Center, Haikou 570206, Hainan Province, China
    2Neonatal Disease Screening Center, Hainan Women and Children′s Medical Center, Haikou 570206, Hainan Province, China
    3Prenatal Diagnosis Center, Hainan Women and Children′s Medical Center, Haikou 570206, Hainan Province, China
  • Received:2026-02-25 Revised:2026-08-24 Published:2026-10-01
  • Corresponding author: Xia Cao
  • Supported by:
    Project of Excellent Talent Team of Hainan Province(QRCBT202121)
Objective

To explore the incidence of various inborn errors of metabolism (IEM) in newborns in Hainan Province.

Methods

A total of 86 543 newborns born in Hainan Province from January 1 to December 31, 2024, whose guardians agreed to undergo neonatal IEM screening, were selected as the study subjects. Using tandem mass spectrometry detection technology, initial and re-screening of various IEM were conducted on dried blood spot specimens collected from the heels of newborn infants. For some newborns who tested positive in the rescreening, peripheral blood was collected, and the type of IEM and gene mutations were confirmed by whole exome sequencing (WES) detection technology. The positive rates of initial IEM screening among newborns of different genders, gestational ages, birth weights, ethnicities, and registered residences were compared by chi-square test, and further pairwise comparisons were performed using the chi-square splitting method, and the Bonferroni method was used to adjust the significance level. This study was conducted in accordance with the ethical standards of Hainan Women and Children′s Medical Center, and was approved by its Ethics Committee (Approval No.HNWCMC-2026-151).

Results

①In 2024, there were 92 170 live births in Hainan Province, and 86 543 of them underwent IEM screening, with an IEM screening rate of 93.89%. Among these 86 543 newborns, the positive rate of initial IEM screening was 3.58% (3 094/86 543). And 2 591 cases underwent IEM rescreening, with an IEM rescreening rate of 83.74% (2 591/3 094). Among them, 245 cases were positive for IEM rescreening, the positive rate of IEM rescreening was 9.46% (245/2 591), and 136 (55.51%, 136/245) newborns underwent genetic testing, and 38 were finally diagnosed with IEM. The incidence rate of IEM in newborns was about 4.39×10-4 (38/86 543). ②The positive rate of initial IEM screening in newborns with gestational age <37 weeks was higher than that in newborns with gestational age ≥37 to 42 weeks, and the difference was statistically significant (χ2=361.64, P<0.001). The overall comparison of the positive rate of initial IEM screening among newborns with different birth weights also showed a statistically significant difference (χ2=291.65, P<0.001). Further pairwise comparisons revealed that the positive rate of initial IEM screening in newborns with birth weight <2 500 g, ≥2 500 to 4 000 g, and >4 000 g differed significantly in any pairwise comparison (P≤0.001). The overall comparison of the positive rate of initial IEM screening among newborns of different ethnic groups showed a statistically significant difference (χ2=36.12, P<0.001). Further pairwise comparisons revealed that the positive rate of initial IEM screening in Li ethnic group newborns was higher than that in Han and Miao ethnic group newborns, and both the differences were statistically significant (P<0.001, P=0.006). The comparison of the positive rate of initial IEM screening among newborns with different registered residence also showed a statistically significant difference (χ2=80.62, P<0.001). Further pairwise comparisons revealed that the positive rate of initial IEM screening in newborns from ethnic minority cities and counties in Hainan Province was higher than that in newborns from Han ethnic group cities and counties in Hainan Province, and the difference was statistically significant (P<0.001). ③Among the 86 543 newborns, the detection rate of IEM-related gene mutation was 7.16×10-4 (62/86 543). The top four detected gene mutations were SLC22A5, SLC25A13, ACADS, and ASS1 gene mutations. The top three detected gene mutation sites were c. 51C>G, c. 852_855del, and c.322G>A, respectively. ④Among the 38 newborns with IEM confirmed by genetic testing, 4 cases were amino acid metabolism disorders, 7 cases were organic acidemia, 5 cases were urea cycle disorders, and 22 cases were fatty acid oxidation metabolism disorders. The top three IEM diseases in terms of confirmed cases were primary carnitine deficiency (13 cases), short-chain acyl-CoA dehydrogenase deficiency (6 cases), and citrullinemia type Ⅱ (5 cases).

Conclusions

The incidence of IEM among newborns in Hainan Province is relatively high, with a diverse range of types. It is recommended to initiate early screening for various IEM in newborns and to enhance the management of infants with positive IEM screening results in Hainan Province.

表1 海南省不同临床特征新生儿IEM初筛阳性率比较
表2 海南省62例检出IEM相关基因突变新生儿的IEM相关基因检出及位点分布情况
突变基因 突变位点/突变类型 例数 携带率(×10-4) 诊断结果a/疾病名称/IEM类型 确诊例数 发病率(×10-4)
ACAD8 c.1000C>T杂合突变/杂合突变 1 0.12 阴性/—/— — —
ACAD8 c.235C>G杂合突变/杂合突变 1 0.12 阴性/—/— — —
ACAD8+ACADM c.286G>A杂合突变+c.1060G>A杂合突变/多基因突变 1 0.12 阴性/—/— — —
ACAD8+ACADSB c.172C>T杂合突变+c.746del杂合突变/多基因突变 1 0.12 阴性/—/— — —
ACADS c.322G>A杂合突变+c.625G>A杂合突变/复合杂合突变 4 0.46 阳性/SCADD/FAOD 4 0.46
ACADS c.322G>A杂合突变/杂合突变 1 0.12 阴性/—/— — —
ACADS c.322G>A杂合突变+c.1031A>G杂合突变/复合杂合突变 1 0.12 阳性/SCADD/FAOD 1 0.12
ACADS c.431C>T杂合突变+c.625G>A杂合突变/复合杂合突变 1 0.12 阳性/SCADD/FAOD 1 0.12
ACADSB c.1165A>G杂合突变+c.655G>A杂合突变/复合杂合突变 1 0.12 阳性/SBCADD/OA 1 0.12
ACADSB c.746del杂合突变+c.655G>A杂合突变/复合杂合突变 1 0.12 阳性/SBCADD/OA 1 0.12
ACADSB c.275C>G杂合突变+c.746del杂合突变/复合杂合突变 1 0.12 阳性/SBCADD/OA 1 0.12
ASS1 c.1087C>T杂合突变/杂合突变 4 0.46 阴性/—/— — —
ASS1 c.773+4A>C杂合突变/杂合突变 2 0.23 阴性/—/— — —
ASS1 c.1168G>A杂合突变/杂合突变 1 0.12 阴性/—/— — —
BCKDHB c.658C>T杂合突变+c.920dup杂合突变/复合杂合突变 1 0.12 阳性/MSUD/AAMD 1 0.12
CPT1A c.1339C>T杂合突变+c.2246G>A杂合突变/复合杂合突变 1 0.12 阳性/CPTⅠ缺乏症/FAOD 1 0.12
CLPB c.1700A>T杂合突变/杂合突变 1 0.12 阴性/—/— — —
CREB3L3 c.157-1G>A杂合突变/杂合突变 1 0.12 阴性/—/— — —
ETFDH c.250G>A杂合突变+c.353G>T杂合突变/复合杂合突变 1 0.12 阳性/GA-Ⅱ/FAOD 1 0.12
GCDH c.1063C>T杂合突变+c.271+1G>A杂合突变/复合杂合突变 1 0.12 阳性/GA-Ⅰ/OA 1 0.12
GCDH c.881G>A杂合突变+c.1063C>T杂合突变/复合杂合突变 1 0.12 阳性/GA-Ⅰ/OA 1 0.12
HLCS c.1564del杂合突变/杂合突变 1 0.12 阴性/—/— — —
MAT1A c.754A>T杂合突变/杂合突变 1 0.12 阳性/MATⅠ与Ⅲ缺乏所致HMM/AAMD 1 0.12
MCCC1 c.2043G>T杂合突变/杂合突变 1 0.12 阴性/—/— — —
MCCC1 c.612del杂合突变/杂合突变 1 0.12 阴性/—/— — —
MCCC2 c.464G>A杂合突变+c.1538T>C杂合突变/复合杂合突变 1 0.12 阳性/MCC2D/OA 1 0.12
MCCC2 c.914A>G杂合突变+c.903+1G>A杂合突变/复合杂合突变 1 0.12 阳性/MCC2D/OA 1 0.12
MMUT c.1208G>A杂合突变/杂合突变 1 0.12 阴性/—/— — —
PAH c.1315+6T>A杂合突变+c.1222C>T杂合突变/复合杂合突变 1 0.12 阳性/PKU/AAMD 1 0.12
PAH c.478C>T杂合突变+c.320A>G杂合突变/复合杂合突变 1 0.12 阳性/PKU/AAMD 1 0.12
SLC22A5 c.51C>G纯合突变/纯合突变 2 0.23 阳性/PCD/UCD 2 0.23
SLC22A5 c.51C>G杂合突变+c.1400C>G杂合突变/复合杂合突变 2 0.23 阳性/PCD/UCD 2 0.23
SLC22A5 c.51C>G杂合突变+c.338G>A杂合突变/复合杂合突变 1 0.12 阳性/PCD/UCD 1 0.12
SLC22A5 c.51C>G杂合突变+c.415G>A杂合突变/复合杂合突变 1 0.12 阳性/PCD/UCD 1 0.12
SLC22A5 c.51C>G杂合突变+c.760C>T杂合突变/复合杂合突变 3 0.35 阳性/PCD/UCD 3 0.35
SLC22A5 c.51C>G杂合突变+c.92C>G杂合突变/复合杂合突变 1 0.12 阳性/PCD/UCD 1 0.12
SLC22A5 c.694A>G杂合突变+c.1064C>T杂合突变/复合杂合突变 1 0.12 阳性/PCD/UCD 1 0.12
SLC22A5 c.844C>T杂合突变/杂合突变 1 0.12 阴性/—/— — —
SLC22A5 c.51C>G杂合突变+c.797C>T杂合突变/复合杂合突变 1 0.12 阳性/PCD/UCD 1 0.12
SLC22A5 c.839C>T杂合突变+c.1064C>T杂合突变/复合杂合突变 1 0.12 阳性/PCD/UCD 1 0.12
SLC22A5 c.769C>T杂合突变/杂合突变 1 0.12 阴性/—/— — —
SLC25A13 c.852_855del杂合突变/杂合突变 2 0.23 阴性/—/— — —
SLC25A13 c.852_855del杂合突变+IVS16ins3Kbp杂合突变/复合杂合突变 1 0.12 阳性/NICCD/UCD 1 0.12
SLC25A13 c.852_855del杂合突变+c.615+5G>A杂合突变/复合杂合突变 2 0.23 阳性/NICCD/UCD 2 0.23
SLC25A13 c.852_855del纯合突变/纯合突变 2 0.23 阳性/NICCD/UCD 2 0.23
SLC25A13 c.1712G>A杂合突变/杂合突变 1 0.12 阴性/—/— — —
SLC25A20 c.199-10T>G杂合突变/杂合突变 1 0.12 阴性/—/— — —
SLC25A20 c.199-10T>G杂合+c.326+1G>A杂合突变/复合杂合突变 1 0.12 阳性/CACTD/FOAD 1 0.12
图1 1例原发性肉碱缺乏症新生儿(女性,39 d龄)及其父母SLC22A5基因Sanger法测序图[图1A:新生儿为c.51C>G纯合突变(箭头所示);图1B、1C:新生儿父亲、母亲均为c.51C>G杂合突变(箭头所示)]
图2 1例枫糖尿病新生儿(女性,14 d龄)及其父母BCKDHB基因Sanger法测序图[图2A、2B:新生儿及其父亲均为c.658C>T杂合突变(箭头所示);图2C:新生儿母亲未检出c.658C>T突变(箭头所示);图2D:新生儿为c.920dup杂合突变(箭头所示);图2E:新生儿父亲未检出c.920dup突变(箭头所示);图2F:新生儿母亲为c.920dup杂合突变(箭头所示)]
图3 1例2-甲基丁酰甘氨酸尿症新生儿(女性,18 d龄)及其父母ACADSB基因Sanger法测序图(图3A、3B:新生儿及其父亲均为c.1165A>G杂合突变(箭头所示);图3C:新生儿母亲未检出c.1165A>G突变(箭头所示);图3D:新生儿为c.655G>A杂合突变(箭头所示);图3E:新生儿父亲未检出c.655G>A突变(箭头所示);图3F:新生儿母亲为c.655G>A杂合突变(箭头所示)]
[1]
石海杰,赵振东. 海南省少数民族地区37 482例新生儿遗传代谢病筛查结果分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2021, 17(1): 30-36. DOI: 10.3877/cma.j.issn.1673-5250.2021.01.005.
[2]
Burlina AB, Corsello G. Survey of Italian pediatricians′ perspectives and knowledge about neonatal screening[J]. Ital J Pediatr, 2015, 41: 41. DOI: 10.1186/s13052-015-0147-1.
[3]
Wang T, Ma J, Zhang Q, et al. Expanded newborn screening for inborn errors of metabolism by tandem mass spectrometry in Suzhou, China: disease spectrum, prevalence, genetic characteristics in a Chinese population[J]. Front Genet, 2019, 10: 1052-1052. DOI: 10.3389/fgene.2019.01052.
[4]
郝会青,付立新,支红霞,等. 105 437例新生儿遗传代谢病串联质谱筛查结果分析[J]. 中国妇幼保健,2020, 35(20): 3837-3839. DOI: 10.19829/j.zgfybj.issn.1001-4411.2020.20.040.
[5]
原卫生部. 新生儿疾病筛查技术规范(2010年版)[EB/OL]. (2010-11-10)[2026-08-09].

URL    
[6]
中华预防医学会出生缺陷预防与控制专业委员会新生儿遗传代谢病筛查学组.新生儿筛查遗传代谢病诊治规范专家共识[J]. 中华新生儿科杂志(中英文), 2023, 38(7): 385-394. DOI: 10.3760/cma.j.issn.2096-2932.2023.07.001.
[7]
中华预防医学会出生缺陷预防与控制专委会新生儿遗传代谢病筛查学组,山东省医学会罕见病分会,山东省罕见疾病协会遗传代谢分会. 新生儿基因筛查流程、结果判读及召回专家共识(2026版)[J]. 中华医学遗传学杂志,2026, 43(3): 171-179. DOI: 10.3760/cma.j.cn511374-20250922-00559.
[8]
陈国梁. 省人大常委会开展《中华人民共和国民族区域自治法》和《海南省实施〈中华人民共和国民族区域自治法〉若干规定》执法检查[J]. 海南人大,2014, 14(8): 17.
[9]
黄国英,孙锟,罗小平. 儿科学[M]. 10版. 北京:人民卫生出版社,2024: 80.
[10]
郭元芳,李改杰,田丽萍,等. 串联质谱筛查新生儿遗传代谢疾病中氨基酸浓度波动性及其影响因素分析[J]. 中国妇幼保健,2018, 33(24): 5886-5889. DOI: 10.7620/zgfybj.j.issn.1001-4411.2018.24.74.
[11]
周婧瑶,张钰,胡琦,等. 影响新生儿氨基酸代谢的多因素分析[J]. 中华实用儿科临床杂志,2020, 35(23): 1773-1776. DOI: 10.3760/cma.j.cn101070-20200109-00042.
[12]
王棋,陈亚平,马骏,等. 苏州市新生儿重症监护室新生儿29项遗传代谢病筛查的影响因素分析[J]. 中国妇幼保健,2023, 38(1): 132-136. DOI: 10.19829/j.zgfybj.issn.1001-4411.2023.01.035.
[13]
McMahon R, DeMartino L, Sowizral M, et al. The impact of seasonal changes on thyroxine and thyroid-stimulating hormone in newborns[J]. Int J Neonatal Screen, 2021,7(1): 8. DOI: 10.3390/ijns7010008.
[14]
van Trotsenburg P, Stoupa A, Léger J, et al. Congenital hypothyroidism: a 2020-2021 consensus guidelines update-an ENDO-European Reference Network initiative endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology[J]. Thyroid, 2021, 31(3): 387-419. DOI: 10.1089/thy.2020.0333.
[15]
国家卫生健康委员会临床检验中心新生儿遗传代谢病筛查室间质评委员会. 新生儿遗传代谢病筛查指标切值建立方法专家共识[J]. 中国实用儿科杂志,2019, 34(11): 881-884. DOI: 10.19538/j.ek2019110601.
[16]
杨雪,李林洁,张晓怡,等. 贵阳地区新生儿遗传代谢疾病串联质谱技术筛查分析[J]. 中国计划生育学杂志,2022, 30(6): 1404-1407. DOI: 10.3969/j.issn.1004-8189.2022.06.041.
[17]
陈琪,朱静潆,冯子奕,等. 新疆地区新生儿遗传代谢病串联质谱筛查的结果分析[J]. 中国优生与遗传杂志,2024, 32(4): 869-873. DOI: 10.13404/j.cnki.cjbhh.2024.04.038.
[18]
白文学,龙川江. 江津区新生儿串联质谱法遗传代谢病筛查研究[J]. 数理医药学杂志,2019, 32(8): 1180-1181. DOI: 10.3969/j.issn.1004-4337.2019.08.036.
[19]
Loeber JG, Platis D, Zetterström RH, et al. Neonatal screening in europe revisited: an ISNS perspective on the current state and developments since 2010[J]. Int J Neonatal Screen, 2021, 7(1):15.DOI: 10.3390/ijns7010015.
[20]
Messina MA, Meli C, Raudino F, et al. Expanded newborn screening using tandem mass spectrometry: seven years of experience in eastern sicily[J]. Int J Neonatal Screen, 2018, 4(2): 12. DOI: 10.3390/ijns4020012.
[21]
Cambra Conejero A, Martinez Figueras L, Ortiz Temprado A, et al. Newborn screening program in the community of Madrid: evaluation of positive cases[J]. Rev Esp Salud Publica, 2020, 94: e202012185.
[22]
Deng K, Zhu J, Yu E, et al. Incidence of inborn errors of metabolism detected by tandem mass spectrometry in China: a census of over seven million newborns between 2016 and 2017[J]. J Med Screen, 2021, 28(3): 223-229. DOI: 10.1177/0969141320973690.
[23]
陈迟,徐益红,吴璀璐,等. 2009—2021年浙江省新生儿遗传代谢病串联质谱法筛查工作质量评价[J]. 预防医学,2022, 34(8): 765-769. DOI: 10.19485/j.cnki.issn2096-5087.2022.08.003.
[24]
Lin Y, Zhang W, Chen Z, et al. Newborn screening and molecular features of patients with multiple acyl-CoA dehydrogenase deficiency in Quanzhou, China[J]. J Pediatr Endocrinol Metab, 2021, 34(5): 649-652.DOI: 10.1515/jpem-2020-0694.
[25]
唐诚芳. 广州地区新生儿遗传代谢病串联质谱法筛查结果及筛查性能评估[J]. 浙江大学学报(医学版), 2021, 50(4): 463-471. DOI: 10.3724/zdxbyxb-2021-0260.
[26]
王欣荣,刘艳秋,官慧珍,等. 126 111例新生儿串联质谱遗传代谢病筛查结果及基因突变情况分析[J]. 江西医药,2022, 57(7): 707-710. DOI: 10.3969/j.issn.1006-2238.2022.07.009.
[27]
朱颖杰,张雯艳,宋萍,等. 105 437例新生儿遗传代谢病串联质谱筛查结果分析[J]. 中国妇幼保健,2020, 35(20): 3837-3839. DOI: 10.19829/j.zgfybj.issn.1001-4411.2020.20.040.
[28]
赵娜,王金玮,李雪燕. 廊坊地区41 062例新生儿遗传代谢病串联质谱筛查结果分析[J]. 中国优生与遗传杂志,2022, 30(3): 504-508. DOI: 10.13404/j.cnki.cjbhh.20220224.001.
[29]
张亚果,苏星月,李婷,等. 四川省部分地区新生儿遗传代谢病串联质谱筛查情况分析[J]. 中国儿童保健杂志,2020, 28(7): 809-812. DOI: 10.11852/zgetbjzz2020-0085.
[1] Haizhu Xu, Fang Li, Zhendong Zhao. Screening and gene mutation analysis of neonatal Citrin deficiency in Hainan Province[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2025, 21(05): 525-533.
[2] Hexuan Zhang, Xue Yang, Lyujin Wang, Linjie Li, Xingyu Liu. Screening and genetic mutation analysis of glucose-6-phosphate dehydrogenase deficiency in neonates[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 200-208.
[3] Zhou Jiang, Li Tang, Liu Yang, Lin Zou. Analysis of influencing factors of diagnosis time in infants with congenital hypothyroidism[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(06): 649-656.
[4] Dongming Li, Sheng He. Research progress on early screening for congenital cytomegalovirus infection[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(06): 627-633.
[5] Lei Liu, Jun Zhu, Lixin Wan, Kui Deng, Yaqiong Yan, Min Li, Yongna Yao, Liangcheng Xiang, Xuelian Yuan, Qi Li, Zheng Liu, Xiaohong Li. Impact of national policies related to neonatal inherited metabolic diseases screening on its coverage rate of midwestern regions in China[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(04): 410-418.
[6] Dayan Wang, Xiaobing Li, Panjian Lai. Analysis of SLC25A13 gene IVS16ins3kb variation in neonatal intrahepatic cholestasis caused by citrin deficiency[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(03): 315-322.
[7] Xiaojing Yu, Yuling Liu, Simao Fu, Xian Xie, Bihong Zhang, Xiaofen Pan, Xiaolin Li, Zhicai Sun. Early screening and follow-up of congenital hydronephrosis[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(05): 582-589.
[8] Wenqing Lu, Xinyi Chen, Xuefei Ren. Investigation on the quality of life after liver transplantation in children with genetic metabolic diseases[J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 287-292.
[9] Yanyun Wang, Dongyang Hong, Xianwei Guan, Xin Wang, Yun Sun. The value of tandem mass spectrometry in detecting arginylsuccinic acid and citrulline levels in the screening of neonatal arginylsuccinic aciduria[J]. Chinese Journal of Diagnostics(Electronic Edition), 2025, 13(04): 225-229.
[10] Xin Gao, Yuanyuan Nian, Xianmei Meng, Xiaoru Yao, Cao Jiaxing. Correlation between metabolic abnormality and disease and gastroesophageal reflux1[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2021, 08(04): 185-188.
[11] Zhulin Xu, Lu Liu, Jinzhou Zhu, Xiaolin Liu. Innovation and progress of bariatric surgery from surgical to endoscopic treatment[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(04): 303-310.
[12] Xiaoyan Gou, Xiaoping Fan, Ran Zou, Yalian Sa, Yong Li. Research progress of bone morphogenetic proteins regulation on brown fat cells[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(02): 148-152.
[13] Yuan Zhang, Zhongyang Zhang, Jiebin Xie, Dianyuan Liang, Zhenghang Yu, Yixing Ren. The mechanism of action and research progress of novel anti-obesity medications[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(01): 11-18.
[14] Yisireyili Maimaiti·, Yiming Yilihan·, Yongkang Wang, Wusiman Ababokeli·, Aili Aikebaier·, Yiliang Li, Abudureyimu Kelimu·. Effects of oxidative stress on GLP-1/DPP-4 signaling pathway and inflammatory factor indicators in 3T3-L1 adipocytes[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 186-191.
[15] XiaoZhuo Tan, Chong Cao, YiKai Shao, QiYuan Yao. The effects of short chain fatty acids on host metabolism[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2022, 08(01): 46-51.
Viewed
Full text


Abstract